A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Pfizer

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: PF-04447943; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00930059

B0401005

2009-012179-82 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.

Enrollment: 191 patients

Sex: All

Ages: 55 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild to moderate Alzheimer's disease (MMSE 14-26)
• Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed)

Exclusion criteria

• Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine within 12 weeks of the start of the study
• Significant cardiovascular disease in the past 6 months
• Illness other than Alzheimer's disease that could contribute to cognitive impairment
• History of stroke or seizure disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

191 participants in 2 patient groups, including a placebo group

PF-04447943

Experimental group

Treatment:

Drug: PF-04447943

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo